Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brilliant-011 phase 1 HIV vaccine trial
PACTR202604518549022Phase 1Unknown
- Sponsor
- South African Medical Research Council
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1 trial of BG505 SOSIP GT1.1 gp140, 426c.Mod.Core-C4b and SMNP in human immunodeficiency virus infection (HIV) (2 arms), sponsored by South African Medical Research Council. Primary endpoints: Safety and tolerability, Env-specific binding antibodies and 1 more. Status: unknown.
02
Drugs
BG505 SOSIP GT1.1 gp140426c.Mod.Core-C4bSMNP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202604518549022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202604518549022.